BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 10364074)

  • 1. All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase.
    Lee C; Sigari F; Segrado T; Hörkkö S; Hama S; Subbaiah PV; Miwa M; Navab M; Witztum JL; Reaven PD
    Arterioscler Thromb Vasc Biol; 1999 Jun; 19(6):1437-46. PubMed ID: 10364074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein.
    Watson AD; Navab M; Hama SY; Sevanian A; Prescott SM; Stafforini DM; McIntyre TM; Du BN; Fogelman AM; Berliner JA
    J Clin Invest; 1995 Feb; 95(2):774-82. PubMed ID: 7860760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblasts that overexpress 15-lipoxygenase generate bioactive and minimally modified LDL.
    Sigari F; Lee C; Witztum JL; Reaven PD
    Arterioscler Thromb Vasc Biol; 1997 Dec; 17(12):3639-45. PubMed ID: 9437216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress.
    Noto H; Hara M; Karasawa K; Iso-O N; Satoh H; Togo M; Hashimoto Y; Yamada Y; Kosaka T; Kawamura M; Kimura S; Tsukamoto K
    Arterioscler Thromb Vasc Biol; 2003 May; 23(5):829-35. PubMed ID: 12649088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility.
    McCall MR; La Belle M; Forte TM; Krauss RM; Takanami Y; Tribble DL
    Biochim Biophys Acta; 1999 Jan; 1437(1):23-36. PubMed ID: 9931415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LDL isolated from Greek subjects on a typical diet or from American subjects on an oleate-supplemented diet induces less monocyte chemotaxis and adhesion when exposed to oxidative stress.
    Tsimikas S; Philis-Tsimikas A; Alexopoulos S; Sigari F; Lee C; Reaven PD
    Arterioscler Thromb Vasc Biol; 1999 Jan; 19(1):122-30. PubMed ID: 9888874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.
    Quarck R; De Geest B; Stengel D; Mertens A; Lox M; Theilmeier G; Michiels C; Raes M; Bult H; Collen D; Van Veldhoven P; Ninio E; Holvoet P
    Circulation; 2001 May; 103(20):2495-500. PubMed ID: 11369691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.
    Eisaf M; Tselepis AD
    Biochem Pharmacol; 2003 Dec; 66(11):2069-73. PubMed ID: 14609731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia.
    Karabina SA; Elisaf M; Bairaktari E; Tzallas C; Siamopoulos KC; Tselepis AD
    Eur J Clin Invest; 1997 Jul; 27(7):595-602. PubMed ID: 9263748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
    Tselepis AD; John Chapman M
    Atheroscler Suppl; 2002 Dec; 3(4):57-68. PubMed ID: 12573364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration.
    Zhang B; Fan P; Shimoji E; Itabe H; Miura S; Uehara Y; Matsunaga A; Saku K
    Atherosclerosis; 2006 Jun; 186(2):291-301. PubMed ID: 16154574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDL, VLDL, chylomicrons and atherosclerosis.
    Nordestgaard BG; Tybjaerg-Hansen A
    Eur J Epidemiol; 1992 May; 8 Suppl 1():92-8. PubMed ID: 1505659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in normal and fructose-fed rats.
    Wójcicka G; Zaręba M; Warpas A; Jamroz-Wiśniewska A; Rusek M; Czechowska G; Bełtowski J
    Eur J Pharmacol; 2019 May; 850():180-189. PubMed ID: 30768981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro.
    Karabina SA; Elisaf MC; Goudevenos J; Siamopoulos KC; Sideris D; Tselepis AD
    Atherosclerosis; 1996 Aug; 125(1):121-34. PubMed ID: 8831934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice.
    Theilmeier G; De Geest B; Van Veldhoven PP; Stengel D; Michiels C; Lox M; Landeloos M; Chapman MJ; Ninio E; Collen D; Himpens B; Holvoet P
    FASEB J; 2000 Oct; 14(13):2032-9. PubMed ID: 11023987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.
    Tsimihodimos V; Kakafika A; Tambaki AP; Bairaktari E; Chapman MJ; Elisaf M; Tselepis AD
    J Lipid Res; 2003 May; 44(5):927-34. PubMed ID: 12611907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia.
    Tsimihodimos V; Karabina SA; Tambaki AP; Bairaktari E; Miltiadous G; Goudevenos JA; Cariolou MA; Chapman MJ; Tselepis AD; Elisaf M
    J Lipid Res; 2002 Feb; 43(2):256-63. PubMed ID: 11861667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3.
    Navab M; Hama SY; Anantharamaiah GM; Hassan K; Hough GP; Watson AD; Reddy ST; Sevanian A; Fonarow GC; Fogelman AM
    J Lipid Res; 2000 Sep; 41(9):1495-508. PubMed ID: 10974057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation.
    Dentan C; Lesnik P; Chapman MJ; Ninio E
    Arterioscler Thromb; 1994 Mar; 14(3):353-60. PubMed ID: 8123638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction.
    Benítez S; Sánchez-Quesada JL; Ribas V; Jorba O; Blanco-Vaca F; González-Sastre F; Ordóñez-Llanos J
    Circulation; 2003 Jul; 108(1):92-6. PubMed ID: 12821559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.